| Mark Berger, NP | |
|
207 E 12th St, Emmett, ID 83617-3626 | |
| (208) 365-1065 | |
| Not Available |
| Full Name | Mark Berger |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 9 Years |
| Location | 207 E 12th St, Emmett, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023471000 | NPI | - | NPPES |
| F1215337 | Other | ID | AANP |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | NP1691A (Idaho) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Alphonsus Medical Center - Ontario, Inc | Ontario, OR | Hospital |
| Valor Health | Emmett, ID | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Valley Family Health Care Inc | 0547169591 | 36 |
| Valley Family Health Care Inc | 0547169591 | 36 |
News Archive
Scientists have established a genetic mouse model for primary ovarian insufficiency (POI), a human condition in which women experience irregular menstrual cycles and reduced fertility, and early exposure to estrogen deficiency.
A report published online February 8 in PLoS Medicine shows that mass behaviour changes could be credited with helping to remarkably reduce the number of people infected with HIV in Zimbabwe in recent years. These changes include declines in extramarital, commercial, and casual sexual relations, as well as a decline in multiple partners. These have been triggered by increased awareness of AIDS deaths and fear of infection and to some extent by the country's economic deterioration.
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect. The product is currently in phase 2b clinical development for the treatment of hepatitis C. Debiopharm granted Novartis worldwide commercialisation rights to Debio 025 except for Japan.
A group of scientists at Helmholtz Zentrum München will engage in a new project promoted by the EU. The scientists in the team of Dr. Jan Hasenauer, head of the young investigator group 'Data-driven Computational Modeling' work as part of CanPathPro.
Pfizer Inc, the world's leading biopharmaceutical company, today announced that the results of a number of hemophilia studies will be presented at the World Federation of Hemophilia 2010 Congress taking place July 10-14, 2010, in Buenos Aires, Argentina. Key research includes a pre-clinical evaluation of recombinant factor Xa as a potential new approach to restoring hemostasis, as well as a study assessing the potential for an engineered recombinant factor VIIa molecule to improve therapeutic outcomes in mouse models of hemophilia.
› Verified 9 days ago
| Entity Name | Valley Family Health Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295415032 PECOS PAC ID: 0547169591 Enrollment ID: O20040305000532 |
News Archive
Scientists have established a genetic mouse model for primary ovarian insufficiency (POI), a human condition in which women experience irregular menstrual cycles and reduced fertility, and early exposure to estrogen deficiency.
A report published online February 8 in PLoS Medicine shows that mass behaviour changes could be credited with helping to remarkably reduce the number of people infected with HIV in Zimbabwe in recent years. These changes include declines in extramarital, commercial, and casual sexual relations, as well as a decline in multiple partners. These have been triggered by increased awareness of AIDS deaths and fear of infection and to some extent by the country's economic deterioration.
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect. The product is currently in phase 2b clinical development for the treatment of hepatitis C. Debiopharm granted Novartis worldwide commercialisation rights to Debio 025 except for Japan.
A group of scientists at Helmholtz Zentrum München will engage in a new project promoted by the EU. The scientists in the team of Dr. Jan Hasenauer, head of the young investigator group 'Data-driven Computational Modeling' work as part of CanPathPro.
Pfizer Inc, the world's leading biopharmaceutical company, today announced that the results of a number of hemophilia studies will be presented at the World Federation of Hemophilia 2010 Congress taking place July 10-14, 2010, in Buenos Aires, Argentina. Key research includes a pre-clinical evaluation of recombinant factor Xa as a potential new approach to restoring hemostasis, as well as a study assessing the potential for an engineered recombinant factor VIIa molecule to improve therapeutic outcomes in mouse models of hemophilia.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark Berger, NP 1441 Ne 10th Ave, Payette, ID 83661-5420 Ph: (208) 365-1065 | Mark Berger, NP 207 E 12th St, Emmett, ID 83617-3626 Ph: (208) 365-1065 |
News Archive
Scientists have established a genetic mouse model for primary ovarian insufficiency (POI), a human condition in which women experience irregular menstrual cycles and reduced fertility, and early exposure to estrogen deficiency.
A report published online February 8 in PLoS Medicine shows that mass behaviour changes could be credited with helping to remarkably reduce the number of people infected with HIV in Zimbabwe in recent years. These changes include declines in extramarital, commercial, and casual sexual relations, as well as a decline in multiple partners. These have been triggered by increased awareness of AIDS deaths and fear of infection and to some extent by the country's economic deterioration.
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect. The product is currently in phase 2b clinical development for the treatment of hepatitis C. Debiopharm granted Novartis worldwide commercialisation rights to Debio 025 except for Japan.
A group of scientists at Helmholtz Zentrum München will engage in a new project promoted by the EU. The scientists in the team of Dr. Jan Hasenauer, head of the young investigator group 'Data-driven Computational Modeling' work as part of CanPathPro.
Pfizer Inc, the world's leading biopharmaceutical company, today announced that the results of a number of hemophilia studies will be presented at the World Federation of Hemophilia 2010 Congress taking place July 10-14, 2010, in Buenos Aires, Argentina. Key research includes a pre-clinical evaluation of recombinant factor Xa as a potential new approach to restoring hemostasis, as well as a study assessing the potential for an engineered recombinant factor VIIa molecule to improve therapeutic outcomes in mouse models of hemophilia.
› Verified 9 days ago
Debra Anne Phillips, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1202 E Locust St, Emmett, ID 83617 Phone: 208-365-3561 Fax: 208-365-4176 | |
Darcy Renee Cook, N.P Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 426 Hwy 16, Emmett, ID 83617 Phone: 208-365-2735 Fax: 208-365-2737 | |
Bobbi Fuller, DNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 709 S. Washington Ave, Suite B, Emmett, ID 83617 Phone: 208-740-8808 | |
Michelle Clapperton, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1108 S Washington Ave, Emmett, ID 83617 Phone: 208-365-3455 Fax: 208-365-3422 | |
Lisa Isaksen, NP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1202 E Locust St, Emmett, ID 83617 Phone: 208-365-3561 | |
Deborah Faye Hollingsworth, MSN, FNP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 3777 Van Dussen Rd, Emmett, ID 83617 Phone: 208-365-0890 Fax: 208-365-0950 |